- Home
- CNTA vs BEAM Comparison
CNTA vs BEAM Comparison
Compare CNTA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- BEAM
- Stock Information
- Founded
- CNTA 2020
- BEAM 2017
- Country
- CNTA United Kingdom
- BEAM United States
- Employees
- CNTA N/A
- BEAM N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNTA Health Care
- BEAM Health Care
- Exchange
- CNTA Nasdaq
- BEAM Nasdaq
- Market Cap
- CNTA 1.8B
- BEAM 1.8B
- IPO Year
- CNTA 2021
- BEAM 2020
- Fundamental
- Price
- CNTA $12.30
- BEAM $17.41
- Analyst Decision
- CNTA Strong Buy
- BEAM Strong Buy
- Analyst Count
- CNTA 10
- BEAM 11
- Target Price
- CNTA $26.11
- BEAM $48.90
- AVG Volume (30 Days)
- CNTA 617.5K
- BEAM 2.2M
- Earning Date
- CNTA 05-20-2025
- BEAM 05-06-2025
- Dividend Yield
- CNTA N/A
- BEAM N/A
- EPS Growth
- CNTA N/A
- BEAM N/A
- EPS
- CNTA N/A
- BEAM N/A
- Revenue
- CNTA N/A
- BEAM $63,578,000.00
- Revenue This Year
- CNTA N/A
- BEAM N/A
- Revenue Next Year
- CNTA N/A
- BEAM $6.32
- P/E Ratio
- CNTA N/A
- BEAM N/A
- Revenue Growth
- CNTA N/A
- BEAM N/A
- 52 Week Low
- CNTA $7.75
- BEAM $13.53
- 52 Week High
- CNTA $19.09
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- CNTA 40.97
- BEAM 43.14
- Support Level
- CNTA $11.88
- BEAM $15.51
- Resistance Level
- CNTA $14.39
- BEAM $20.90
- Average True Range (ATR)
- CNTA 0.79
- BEAM 1.22
- MACD
- CNTA -0.00
- BEAM -0.03
- Stochastic Oscillator
- CNTA 18.68
- BEAM 35.25
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.